## Please fax all pages of completed form to your team at 888.302.1028.

To reach your team, call toll-free 844.516.3319.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Prescription & Enrollment Form

Kisunla<sup>TM</sup> (donanemab-azbt)



## Four simple steps to submit your referral.

1 Patient Inform	ation		Please provide copies of from and prescription insurance co	
New patient Current pati	ent			
Patient's first name		Last name _		Middle initial
Preferred patient first name		Pre	ferred patient last name	
Sex at birth: Male Female	Gender identity	Pronouns	Last	4 digits of SSN
Date of birth	Street address			Apt #
City		State		Zip
Home phone	Cell phone		Email address	
Parent/guardian (if applicable) _				
Alternate caregiver/contact				
OK to leave message with alte	rnate caregiver/contact			
Patient's primary language: E	Inglish Other If othe	r, please specify		
Date Office/clinic/institution name				
Prescriber info: Prescriber's first	st name Last name			
Prescriber's title		If NP or PA,	under direction of Dr	
Office phone	Fax	NPI #	Li	cense #
Office contact and title			Office contact email	
Office street address				Suite #
City		State		Zip
Infusion location: Patient's hor	ne Prescriber's office	Infusion site If infu	sion site, complete informatio	n below dotted line:
Infusion info: Infusion site name		Clir	nic/hospital affiliation	
Site street address				Suite #
City		State		Zip
Infusion site contact	Phon	e	Fax Emai	I
3 Clinical Inform	nation			
Primary ICD-10 code (REQUIRE	O):	Has the p	atient been treated previously	for this condition? Yes N
Is the patient currently on therap		·	, ,	
Patient wt C NKDA Known drug allergi				
Concurrent meds				

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Pr	one
Diagnosis: G30.0 Alzheimer's disease with early onset		st MRI negative for ARIA: of amyloid positivity confirmed	
G30.1 Alzheimer's disease with late onset G30.8 Other Alzheimer's disease G30.9 Alzheimer's disease, unspecified G31.84 Mild cognitive impairment, so stated	PET scan CSF sample		
Other:			

## 4 Prescribing Information

Medication/Strength	Directions	Quantity/Refills
Kisunla™ (donanemab-azbt) 350mg/20mL (17.5mg/mL) single-dose vial  Medicare beneficiaries (required by CMS):  NCT registry number:	Starting Dose: Infuse 700mg (two vials) intravenously over approximately 30 minutes once every 4 weeks for Infusions 1, 2, and 3  If patient needs partial starting dose, indicate what is needed:  Infusion 2 and Infusion 3  Infusion 3 only	2 vials/28 days supply Refills: 2 Other
CED submission number:	Maintenance Dose: Infuse 1400mg (four vials) intravenously over approximately 30 minutes at infusion 4 and then once every 4 weeks thereafter	4 vials/28 days supply Refills: Other
CED submission date:	Observe the patient post-infusion for a minimum of 30 minutes to evaluate for infusion reactions and hypersensitivity reactions.	
CED Registry Link: https://qualitynet.cms.gov/ alzheimers-ced-registry	alitynet.cms.gov/	

Dispense needles, syringes, ancillary supplies and home medical equipment necessary to administer medication.

If shipped to physician's office, physician accepts on behalf of patient for administration in office.

Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN				
HERE	Date	Dispense as written	Date	Substitution allowed
		•		

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

